ClinicalTrials.gg
CompletedNCT04383873Updated Apr 18, 2022

Effectiveness Analysis of Armeo Spring Device as a Rehabilitation Treatment in Spinal Cord Injured Patients

An interventional study of Training by means of Armeo Spring device and Current treatment based on conventional therapy in Spinal Cord Injury Cervical, sponsored by Hospital Nacional de Parapléjicos de Toledo. Completed at 1 site in Spain. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-04-18.

Sponsored by Hospital Nacional de Parapléjicos de Toledo · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 10 months after the study started (first participant enrolled Jun 2016, registered Apr 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
16 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Spinal Cord Injuries with a site in Spain — 12 open to participants now, 13 under way, 1 of them phase 3. Spinal Cord Injuries · Spain.

Enrollment
26th of 55
34 · median 30
Started
2016
with 3 others
No phase
34 of 59
9 open now
Registered
29th of 59
by date
Lead sponsor
6 of 59
Hospital Nacional de Parapléjicos de Toledo

Among the 59 studies in Spinal Cord Injuries with a site in Spain, this one is the 26th largest by enrollment of the 55 interventional ones that give a count, is one of 4 that started in 2016, is one of 34 with no phase, and was the 29th registered.

Spinal Cord Injuries

2,028 studies on the registry are indexed under Spinal Cord Injuries; 540 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

12 of the 59 studies in Spinal Cord Injuries with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 376 Spinal Cord Injuries studies recruiting now, 167 (44%) set no upper age limit and 158 (42%) stop at 75 or younger; 41 take children under 18; 52 take healthy volunteers.

This study: 16 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Spinal Cord Injuries with a site in Spain, or all of them as a file.
02

Study summary

Loss of motor function is a consequence after a spinal cord injury (SCI). The incidence of SCI varies greatly from 12.1 to 57.8 cases per million depending on the country. More than 50% of people with SCI have impaired upper limb (UL) function, experiencing limitations in performing functional tasks. In this context, one of the rehabilitation objectives is to achieve the maximum level of independence in the patient in the performance of activities of daily living (ADL).

Within the clinical setting, the main motivation in the use of robotic devices and/or exoskeletons for a rehabilitation purpose focuses on the fact that these help therapists in administering repetitive manual therapies to patients during exercises. There is evidence that the amount of therapy patients receive is insufficient. Without creating additional time demands on clinicians, robotic devices can perform the repetitive mechanical aspects of therapy, increasing the amount of therapy that patients receive. However, the current evidence in stroke patients suggests that the improvements observed are due to the intensity of the therapy, regardless of whether the administration of rehabilitation is due to robotic devices and/or traditional means.

The main objective of this study is to analyze the effectiveness of the commercial Armeo® Spring system (Hocoma AG, Switzerland) and a Virtual Reality application to repeatedly work the ADL from drinking from a glass, in people with cervical SCI. The ADL of drinking has been chosen, as a representative activity of those related to food, which requires control, strength and coordination of the UL. The study is carried out at the Hospital Nacional de Parapléjicos with the collaboration of Occupational Therapy Unit, the Rehabilitation Department, and the Biomechanics and Technical Aids Unit. This effectiveness is measured in terms of functional improvements and in the quality of the UL movements performed.

Read the detailed description

In the literature, there are several studies of the upper limb applied to ADL. The analysis of complete ADL is related to the clinical objectives of the rehabilitative treatment of the UL. An important part of rehabilitation after neurological injuries consists of training activities aimed at fulfilling a function or objective, in which patients have to move their arms continuously repeating certain movement patterns. This is currently one of the main strategies to promote recovery of upper limb function in people who have suffered a spinal cord injury (SCI) o stroke.

Within the clinical setting, the main motivation in the use of robotic devices and/or exoskeletons for a rehabilitation purpose focuses on the fact that these help therapists in administering repetitive manual therapies to patients during exercises. There is evidence that the amount of therapy patients receive is insufficient. Without creating additional time demands on clinicians, robotic devices can perform the repetitive mechanical aspects of therapy, increasing the amount of therapy that patients receive. On the other hand, the use of robotic devices is closely linked to the use of virtual reality (VR) applications. VR interfaces provide feedback to the patient, increasing their level of motivation and adherence to the task during therapy. In this way, therapies with robotic devices and / or exoskeletons increase the amount of rehabilitation, the level of motivation of the patient, and training oriented to fulfill a function or task. Rehabilitation of patients with robotic device-based therapies in addition to traditional therapies could improve functional outcomes. However, the current evidence in stroke patients suggests that the improvements observed are due to the intensity of the therapy, regardless of whether the administration of rehabilitation is due to robotic devices and/or traditional means.

The main objective of this study is to analyze the effectiveness of the commercial Armeo® Spring system (Hocoma AG, Switzerland) and a Virtual Reality application to repeatedly work the ADL from drinking from a glass, in people with cervical SCI. The ADL of drinking has been chosen, as a representative activity of those related to food, which requires control, strength and coordination of the UL. The study is carried out at the Hospital Nacional de Parapléjicos with the collaboration of Occupational Therapy Unit, the Rehabilitation Department, and the Biomechanics and Technical Aids Unit. This effectiveness is measured in terms of functional improvements and in the quality of the UL movements performed.

The secondary objectives are:

  • To validate the applicability of the Virtual Reality developed to work the upper limb during the execution of a complete AVD.
  • To know the usability and level of acceptance of this therapy in patients with spinal cord injury and UL functional impairments.
  • To quantify the differences between the functional patterns of both groups, intervention and control, by means of objective measures, functional scales and measures of the quality of movement, collected in patient evaluations, before, during and after treatment.
  • To determine the influence of the RV and the Armeo Spring exoskeleton on the motor recovery of patients with spinal cord injury and UL impairments.
03

Conditions studied

  • Spinal Cord Injury Cervical

Keywords

  • Effectiveness
  • Rehabilitation
  • Upper extremity
  • Spinal Cord Injury cervical
  • Robotic device
04

Who can participate

Ages eligible
16 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cervical lesions above C8, incomplete in the motor aspect or complete with zones of partial motor preservation at least C6, classified according to the ASIA scale.
  • Traumatic or non-progressive medical etiology.
  • Less than 6 months of injury evolution (subacute).
  • Age between 16 and 75 years.
  • To have reached the seated posture.
  • Be informed and consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Unstable orthopaedic injuries such as unconsolidated fractures or with unstable osteosynthesis systems in upper limbs.
  • Skin lesions and/or pressure ulcers in the exoskeleton placement area.
  • Having joint stiffness and/or severe spasticity.
  • Bronchopneumopathy and/or severe heart disease that will require monitoring during exercise.
  • Visual problems.
  • Cognitive impairment.
  • Do not sign the corresponding .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Intervention

    17 cervical Spinal Cord injured patients daily receive 1 hour of upper extremity therapy

    Device: Training by means of Armeo Spring device · Other: Current treatment based on conventional therapy

  • Active comparator
    Control

    17 cervical Spinal Cord injured patients daily receive 1 hour of upper extremity therapy

    Other: Current treatment based on conventional therapy · Other: Additional treatment based on conventional therapy

Interventions

  • DeviceTraining by means of Armeo Spring device

    This patients group receive 40 experimental sessions. Each session is based on 30 min by using Armeo Spring device.

  • OtherCurrent treatment based on conventional therapy

    All the patients enrollment in the study receive 30 min of conventional therapy during 40 sessions.

  • OtherAdditional treatment based on conventional therapy

    This intevention was added for providing the same amount of therapy than those patients randomly enrolled in the intervention group. So, patients in the control group receive other 30 min of conventional therapy added on current treatment during 40 sessions.

06

What researchers measure

Primary outcomes

  1. Clinical scale SCIM

    The Spinal Cord Independence Measure (SCIM) is a new disability scale developed specifically for patients with spinal cord lesions in order to make the functional assessments of patients with paraplegia or tetraplegia more sensitive to changes. Exclusively designed for spinal injury. It consists of 3 subscales. The total score varies from 0-100 points, where 0 corresponds to the highest degree of dependency and 100 to the highest degree of independence.

    Time frame: At baseline

  2. Change from baseline Clinical scale SCIM at 10 weeks

    The Spinal Cord Independence Measure (SCIM) is a new disability scale developed specifically for patients with spinal cord lesions in order to make the functional assessments of patients with paraplegia or tetraplegia more sensitive to changes. Exclusively designed for spinal injury. It consists of 3 subscales. The total score varies from 0-100 points, where 0 corresponds to the highest degree of dependency and 100 to the highest degree of independence.

    Time frame: At the end of the study (at week 10)

  3. Clinical scale CUE

    Capabilities of Upper Extremity (CUE) measures upper extremity functional limitations in individuals with tetraplegia. The patient reports the outcome about how well you are able to use the arms and hands of patients. 32 item questionnaire with items in 7 domains. Self-reported measure performed by interview. Score on 7 points scale representing self-perceived difficulty: 1 (Totally limited, can´t do at all) y 7 (Not at all limited). So, the minimum score is 32 (worse result) and the maximum score 224 (greater function)

    Time frame: At baseline

  4. Change from baseline Clinical scale CUE at 10 weeks

    Capabilities of Upper Extremity (CUE) measures upper extremity functional limitations in individuals with tetraplegia. The patient reports the outcome about how well you are able to use the arms and hands of patients. 32 item questionnaire with items in 7 domains. Self-reported measure performed by interview. Score on 7 points scale representing self-perceived difficulty: 1 (Totally limited, can´t do at all) y 7 (Not at all limited). So, the minimum score is 32 (worse result) and the maximum score 224 (greater function)

    Time frame: At the end of the study (at week 10)

  5. Clinical Scale Jebsen-Taylor Hand Function (JTHF)

    The Jebsen-Taylor function test was designed to provide a short, objective test of hand functions commonly used in activities of daily living (ADLs). The target patient population includes adults with neurological or musculoskeletal conditions involving hand disabilities, although there may be other patient populations with other hand dysfunctions which may be appropriate. It consists of seven items that include a range of fine motor, weighted and non-weighted hand function activities which are timed: writing (copying) a 24-letter sentence turning over a 3 × 5" cards, picking up small common objects such as a coin and bottle cap, simulated feeding using a teaspoon and five kidney beans, stacking checkers picking up large light objects such as an empty tin can, and picking up and moving large weighted cans. The scale measures the time in seconds in reaching each task. A higher spent time is a worse outcome.

    Time frame: At baseline

  6. Change from baseline Clinical Scale Jebsen-Taylor Hand Function (JTHF) at 10 weeks

    The Jebsen-Taylor function test was designed to provide a short, objective test of hand functions commonly used in activities of daily living (ADLs). The target patient population includes adults with neurological or musculoskeletal conditions involving hand disabilities, although there may be other patient populations with other hand dysfunctions which may be appropriate. It consists of seven items that include a range of fine motor, weighted and non-weighted hand function activities which are timed: writing (copying) a 24-letter sentence turning over a 3 × 5" cards, picking up small common objects such as a coin and bottle cap, simulated feeding using a teaspoon and five kidney beans, stacking checkers picking up large light objects such as an empty tin can, and picking up and moving large weighted cans. The scale measures the time in seconds in reaching each task. A higher spent time is a worse outcome.

    Time frame: At the end of the study (at week 10)

  7. Clinical scale Nine Hole Peg Test

    The Nine-Hole Peg Test (9-HPT) is a standardized, quantitative assessment used to measure finger dexterity. The scale measures the time in seconds in reaching each task. A higher spent time is a worse outcome.

    Time frame: At baseline

  8. Change from baseline Clinical scale Nine Hole Peg Test at 10 weeks

    The Nine-Hole Peg Test (9-HPT) is a standardized, quantitative assessment used to measure finger dexterity. The scale measures the time in seconds in reaching each task. A higher spent time is a worse outcome.

    Time frame: At the end of the study (at week 10)

  9. Clinical Scale GRASSP

    The GRASSP is a clinical impairment measure specific to the upper limb for use after tetraplegia. The GRASSP measure sensorimotor and prehension function through three domains, important in describing arm and hand function: Strength, Sensation, Prehension. The minimal score is 0 (worse outcome) and the maximum 98 (better outcome) for each hand.

    Time frame: At baseline

  10. Change from baseline Clinical Scale GRASSP at 10 weeks

    The GRASSP is a clinical impairment measure specific to the upper limb for use after tetraplegia. The GRASSP measure sensorimotor and prehension function through three domains, important in describing arm and hand function: Strength, Sensation, Prehension. The minimal score is 0 (worse outcome) and the maximum 98 (better outcome) for each hand.

    Time frame: At the end of the study (at week 10)

  11. Edinburg Handedness Test

    Most people are right handed. The Edinburgh Handedness Inventory is a well known short questionnaire for determining objectively whether one is left or right handed and there is a short form of it. 10 items are valued. The total score is 50 points and the minimum 10 points. The closer score to 50 points, more left-handed the person is. And the closer score to 10 the more right-handed.

    Time frame: At baseline

  12. Kinematic indices

    This assessment is performed by means of photogrammetry. Markers are placed on the trunk and the arm analyzed, and kinematic variables about the UL movement are computed in terms of accuracy, agility, coordination, efficiency and smoothness. A score of 100 in each index corresponds to the healthy pattern. The minimun and worse outcome is 0 score.

    Time frame: At baseline

  13. Change from baseline Kinematic indices at 10 weeks

    This assessment is performed by means of photogrammetry. Markers are placed on the trunk and the arm analyzed, and kinematic variables about the UL movement are computed in terms of accuracy, agility, coordination, efficiency and smoothness. A score of 100 in each index corresponds to the healthy pattern. The minimun and worse outcome is 0 score.

    Time frame: At the end of the study (at week 10)

Secondary outcomes

  1. Compliance

    The total sessions number that the patient has performed and the duration in weeks

    Time frame: At the end of the study (at week 10)

  2. QUEST usability scale

    At ending the treatment using Armeo Spring, patients show their opinion and satisfaction level with the experimental scenario

    Time frame: At the end of the study (at week 10)

  3. TMS assessment

    A transcranial magnetic stimulation-based assessment is made.

    Time frame: At baseline

  4. Change from baseline TMS assessment at 10 weeks

    A transcranial magnetic stimulation-based assessment is made.

    Time frame: At the end of the study (at week 10)

  5. Beck's Depression Inventory

    This depression inventory can be self-scored. The scoring scale is at the end of questionnaire. the BDI consists of 21 items, self-reporting inventory for assessing depression, with 4 alternatives each that are rated from 0 to 3, giving a possible total of 0 to 63 points. The interpretation of the score is as follows: From 1-10 points: These ups and downs are considered normal; from 11-16 points: Slight disturbance of mood; from 17-20 points: Intermittent states of depression. From 21-30 points: Moderate depression. 31-40 points: Severe depression; More than 40 points: Extreme depression.

    Time frame: At baseline

  6. Change from baseline Beck's Depression Inventory at 10 weeks

    This depression inventory can be self-scored. The scoring scale is at the end of questionnaire. the BDI consists of 21 items, self-reporting inventory for assessing depression, with 4 alternatives each that are rated from 0 to 3, giving a possible total of 0 to 63 points. The interpretation of the score is as follows: From 1-10 points: These ups and downs are considered normal; from 11-16 points: Slight disturbance of mood; from 17-20 points: Intermittent states of depression. From 21-30 points: Moderate depression. 31-40 points: Severe depression; More than 40 points: Extreme depression.

    Time frame: At the end of the study (at week 10)

  7. Hospital Anxiety and Depression Scale (HADS)

    The HADS is a questionnaire widely used to evaluate the anxiety and depression. The HADS takes between 2 to 5 minutes to complete. The HAD contains seven subscales for each mood (anxiety and depression). The HAD Scale is an effective screening instrument and ranges of scores are given in order that the proportion of false positives or false negatives may be minimized. Regarding the scores obtained, a score equal to or greater than 11 is considered depression/anxiety. Between 0 and 7 is not considered depression/anxiety, and between 8 and 10 is doubtful case.

    Time frame: At baseline

  8. Change from baseline Hospital Anxiety and Depression Scale (HADS) at 10 weeks

    The HADS is a questionnaire widely used to evaluate the anxiety and depression. The HADS takes between 2 to 5 minutes to complete. The HAD contains seven subscales for each mood (anxiety and depression). The HAD Scale is an effective screening instrument and ranges of scores are given in order that the proportion of false positives or false negatives may be minimized. Regarding the scores obtained, a score equal to or greater than 11 is considered depression/anxiety. Between 0 and 7 is not considered depression/anxiety, and between 8 and 10 is doubtful case.

    Time frame: At the end of the study (at week 10)

07

Study locations

1 site
  • Hospital Nacional de Parapléjicos
    Toledo, 45071, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Nov 2021, 65 months.

Of 790 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's 65 months is above that.

Counting every sponsor, half of 839 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2020
First posted
May 12, 2020
StartActual
Jun 18, 2016
Primary completionActual
Nov 30, 2021
CompletionActual
Dec 28, 2021
Last update
Apr 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04383873
Lead sponsor
Hospital Nacional de Parapléjicos de Toledo
Responsible party
Ana de los Reyes Guzmán (Principal Investigator, Hospital Nacional de Parapléjicos de Toledo) — Principal investigator
First posted
May 12, 2020
Start date
Jun 18, 2016
Primary completion
Nov 30, 2021
Completion
Dec 28, 2021
Last update
Apr 18, 2022

Study contacts

Ana de los Reyes, PhD
principal investigator · Hospital Nacional de Parapléjicos

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion